Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Feedback ( (GB:FDBK) ) has issued an announcement.
Feedback PLC’s half-year trading update reveals that the company’s revenue remained steady at approximately £0.4m, with a significant portion generated from its Bleepa platform. The company successfully raised £6.1m to support growth initiatives, including a collaboration with a UK primary care partner and the expansion of Bleepa under the Elective Recovery Fund (ERF). Feedback has developed strategic partnerships to capitalize on NHS digitization efforts, positioning itself for growth with potential contracts worth over £2m per annum per Integrated Care Board (ICB). The company is piloting a Neighbourhood Diagnostics Platform to enhance community healthcare delivery and anticipates a significant market opportunity. With a growing pipeline of engagements, Feedback is poised to convert opportunities into revenue streams in the near term.
More about Feedback
Feedback PLC is a clinical infrastructure specialist focusing on enhancing clinician access to patient data and facilitating collaboration among remote clinical teams. Their primary products, Bleepa® and CareLocker®, work together to provide a digital infrastructure that allows clinicians to access and interact with patient data across multiple settings, aiming to improve decision-making and patient care. The company operates a scalable Software as a Service (SaaS) model, targeting growth opportunities within the NHS, private healthcare providers, and international markets.
YTD Price Performance: -73.70%
Average Trading Volume: 130,231
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £7.78M
For an in-depth examination of FDBK stock, go to TipRanks’ Stock Analysis page.
